Cover
Vol. 4 No. 2 (2014)

Published: December 31, 2014

Pages: 14-18

Research Article

Prevalence and Presenting Features of Polycystic Ovarian Syndrome in Iraqi Obese Females

Faris Abdul Kareem Khazaal 1 Abdul Hadi Liebi Insaf Jasim Mahmoud
1Obesity Research and Therapy Unit Al-Kindy College of Medicine-University of Baghdad-Baghdad, IRAQ
History
  • Received: September 1, 2014
  • Available Online: December 1, 2014

Abstract

Background: Polycystic ovarian syndrome (PCOS) constitutes the most common endocrinopathy of women of reproductive age. Women with PCOS manifest hyperandrogenemia, hyperinsulinemia, and hypothalamic-pituitary-ovarian axis aberrations. Objective: The objective of the present study was to find the prevalence and the presenting features of PCO patients and associated manifestations in relation to biochemical and anthropometric parameters in adult obese women attending obesity research and therapy unit. Methods: Patients diagnosed as PCOS according to Androgen Excess and PCOS Society/2009 criteria were grouped into two groups: those with BMI less than 30kg/m2 and those with BMI 30kg/m2 and more. Blood was drawn for biochemical and hormonal assay. Information tabulated, means and percentages used, and the results were analyzed. Results: The number of adult females 20-40 years of age attending Obesity research and therapy unit (ORTU) during February 2013 to February 2014 was 756, (14.3%) of them had PCOS, (65%) were diagnosed during examination. (94.4%) had menstrual disturbances, (63.8%) had hirsutism and (91.7%) had PCOS ultrasound findings. Mean BMI of the patients with PCOS was 33.62 (SD 4.21). Mean LH exceeded mean FSH in patients with PCOS and it was more evident with increasing BMI where it was doubled in those with BMI more than 30 kg/m2. LH/FSH ratio for BMI above 30 was 2.1, and although testosterone level was elevated showed no statistical relation to BMI. The fasting glucose level, cholesterol and triglycerides levels showed the same pattern of elevation that with increasing BMI. Conclusions: The prevalence of PCOS in females (20-40y) attending ORTU was 14%, of them 65% were undiagnosed before, 63% had hirsutism, 94% had menstrual disturbances and 90% had ultrasonic features of polycystic ovary. These findings suggest the need to stress on diagnosing PCOS in adult female during management of obesity.

Keywords

References

  1. Macut D, Pfeifer M, Yildiz BO, Diamanti-Kandarakis E (eds): Polycystic Ovary Syndrome. Novel Insights into Causes and Therapy. Front Horm Res. Basel, Karger, 2013, vol 40, pp 1–21
  2. Michelmore KF, Balen AH, Dunger DB,Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf ) 1999;51: 779-86
  3. Polson DW, Adams J, Wadsworth J,Franks S. Polycystic ovaries — a common finding in normal women. Lancet 1988;1: 870-2.
  4. Frank S. adult polycystic ovary syndrome begins in childhood. Best Pract Res. Clin Endocrin Met. 2002:16: 263-72.
  5. Eisner JR, Dumesic DA, Kemnitz JW,Colman RJ, Abbott DH. Increased adiposity in female rhesus monkeys exposed to androgen excess during early gestation. ObesRes 2003;11:279-86
  6. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome- a hypothesis. J Endocrinol 2002; 174:1-5
  7. Dunaif A., Thomas A. Current Concepts in polycystic ovary syndrome. Ann Rev Med. 2001: 52: 401-419.
  8. Michael T. Sheehan, MD. Polycystic Ovarian Syndrome: Diagnosis and Management. Clin Med Res. Feb 2004; 2(1): 13–27.
  9. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF; Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009 Feb;91(2):456-88.
  10. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria.Hum Reprod. 2010;25(2):544.
  11. Lyndal Harborne, Richard Fleming, Helen Lyall, Naveed Sattar, and Jane Norman. Metformin or Antiandrogen in the Treatment of Hirsutism in Polycystic Ovary Syndrome.The Journal of Clinical Endocrinology & Metabolism.2003.Volume 88, Issue 9.
  12. Brassard M, AinMelk Y, Baillargeon JP. Basic infertility including polycystic ovary syndrome.Med Clin North Am. 2008;92:1163–1192.
  13. Lujan ME, Jarrett BY, Brooks ED, Reines JK, Peppin AK, Muhn N, Haider E, Pierson RA, Chizen DR. Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume. Hum Reprod. 2013 May;28(5):1361-8.
  14. Robinson S, Rodin DA, Deacon A, Wheeler MJ, Clayton RN. Which hormone tests for the diagnosis of polycystic ovary syndrome?. Br J Obstet Gynaecol. 1992 Mar;99(3):232-8.
  15. Carmina E, Rosato F, Maggiore M, Gagliano AM, Indovina D, Jannì A. Prolactin secretion in polycystic ovary syndrome (PCO): correlation with the steroid pattern.. Acta Endocrinol (Copenh). 1984 Jan;105(1):99-104.
  16. Hudecova M, Holte J, Olovsson M, Larsson A, Berne C, Poromaa IS. Diabetes and impaired glucose tolerance in patients with polycystic ovary syndrome--a long term follow-up. Hum Reprod. 2011 Jun;26(6):1462-8.
  17. Wild RA, Alaupovic P, Parker IJ. Lipid and apolipoprotein abnormalities in hirsute women. Am J Obstet Gynecol 1992;166:1191-7.
  18. Cristian-Ioan IUHAS, Nicolae COSTIN, and Dan MIHU Lipid Parameters in Patients with Polycystic Ovary Syndrome. Applied Medical Informatics. Vol. 31, No. 4 /2012, pp: 27-32